Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.

Genetics and molecular research : GMR - 13 Feb 2014

Zhang M, Yang Y, Zhao G, Di X, Xu L, Jiang N, Xu J, Xu X

Abstract excerpt

The aim of this study was to investigate the effect of the CYP2C9*3 (CYP2C9 1075 A>C) polymorphism on meloxicam pharmacokinetics in a Chinese population. Twenty-four healthy volunteers were enrolled in this study. The pyrosequencing technique was used to identify polymorphisms of CYP2C9. The concentration of meloxicam in plasma was determined by a high-performance liquid chromatography assay with mass...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to China
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Healthy Volunteers

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Thiazoles

Source

Identifiers

PMID: 24615047
DOI: 10.4238/2014.February.13.1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.PMID 24615047Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.Semantic proximity Read ↗

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.Semantic proximity Read ↗

Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.Semantic proximity Read ↗

Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Semantic proximity Read ↗

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Semantic proximity Read ↗

Effect of the CYP2C9*3 allele on lornoxicam metabolism.Semantic proximity Read ↗

Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.Semantic proximity Read ↗

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.Semantic proximity Read ↗

Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.Semantic proximity Read ↗

The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem.Semantic proximity Read ↗

Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.